Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Major Depressive Disorder: full-pipeline trial registry
109 of 283 indexed Major Depressive Disorder trials are currently recruiting.
Corpus placement: #33 of 28,707 conditions by registered trial count.
283 US clinical trials · 109 currently recruiting · #33 of 28,707 conditions by registered trial count
Major Depressive Disorder: 283 US clinical trials tracked, 109 recruiting.
Major Depressive Disorder is the subject of 283 registered US clinical trials on ClinicalTrials.gov, 109 of them currently open to new participants. 74 are in Phase 3-4 (later-stage) and 81 in Phase 1-2 (earlier-stage). The most active sponsor is Massachusetts General Hospital, running 19 of these trials.
Enrollment posture brief
Registry condition major-depressive-disorder
OPEN 109 | RECR 39% | LATE 74 | EARLY 81 | RANK #33 | SPON 19
Volume-matched condition peers
Nearest open-share peer: Anaplastic Oligodendroglioma (38% recruiting · 13 trials)
Major Depressive Disorder lists 109 open slots (39% of 283 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Major Depressive Disorder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Major Depressive Disorder recruits in line with its size-band peers.
109 of 283 indexed trials (38.5%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Major Depressive Disorder trials is spread across many organizations.
Massachusetts General Hospital accounts for 19 of 283 trials (6.7%). 118 distinct sponsors appear on at least one study for this condition label.
-
Typical Major Depressive Disorder enrolment sits around 81 participants.
Median target enrolment is 81 among the 283 trials that report a genuine target (sentinel values excluded). 145 of those (51.2%) plan for fewer than 100 participants.
-
Major Depressive Disorder research is mostly interventional.
258 interventional and 25 observational studies make up this index (91.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
283 total, page 2 of 6
Brain Changes During Social Reward Psychotherapy for Mid- and Late-Life Suicidality
Weill Medical College of Cornell University
NCT05925322
Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV
Massachusetts General Hospital
NCT05570812
Imaging Depression in Parkinson's Disease
Yale University
NCT06402955
Neural Circuit Effects of Ketamine in Depression
Icahn School of Medicine at Mount Sinai
NCT06213324
Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression - R33
NYU Langone Health
NCT05573074
5-HTP and Creatine for Depression R33 Phase
University of Utah
NCT05895747
Psilocybin rTMS for Treatment Resistant Depression
University of Texas at Austin
NCT06132178
Exercise-priming of CBT for Depression: the CBT+ Trial
University of Wisconsin, Madison
NCT07221929
JAK Signaling in Depression
Emory University
NCT07003997
Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
Massachusetts General Hospital
NCT05450432
Near Infrared Spectroscopy (NIRS) for Assessment of Depression
University of California, San Francisco
NCT04061148
Targeting Network Dysfunction in Apathy of Late-life Depression Using Digital Therapeutics
AdventHealth
NCT05877885
Neural Correlates of Stress and Perceived Control in Adolescent Depression
Mclean Hospital
NCT04788524
Mindful Self-compassion for Anxiety and Depression: Impact of Delivery Method
Georgetown University
NCT07028216
Targeting Specific Brain Networks to Treat Specific Symptoms in Depression
Massachusetts General Hospital
NCT05523817
Network Neurofeedback Using 7-Tesla MRI to Reduce Rumination Levels in Depression
Icahn School of Medicine at Mount Sinai
NCT05933148
Sequential Bilateral Accelerated Theta Burst Stimulation in Adolescents With Suicidal Ideation
Mayo Clinic
NCT04502758
Maintenance rTMS for Depression (Maitr-De)
University of California, San Diego
NCT06938841
Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression
University of North Carolina, Chapel Hill
NCT06610305
Causal Role of Delta-beta Coupling for Goal-directed Behavior in Anhedonic Depression
Florida State University
NCT06132581
Targeting Large-scale Networks in Depression With Real-time Functional Magnetic Resonance Imaging (fMRI) Neurofeedback
University of Michigan
NCT06050070
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
National Institute of Mental Health (NIMH)
NCT03973268
Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression
Icahn School of Medicine at Mount Sinai
NCT06559826
Mindfulness Engaged Neurostimulation for Depression
University of California, San Diego
NCT06399406
Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder
Icahn School of Medicine at Mount Sinai
NCT06592833
Aβ Dynamics in LLMD
NYU Langone Health
NCT05004987
Two Doses of Psilocybin for the Treatment of MDD in Adults With Cancer
Sunstone Medical
NCT05947383
Pain and Major Depressive Disorder
University of California, Los Angeles
NCT04556890
Closed-loop Optimized rTMS for Depression
Stanford University
NCT04142320
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
Temple University
NCT06336616
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Neurocrine Biosciences
NCT07105111
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
University of Texas at Austin
NCT05892744
Accelerated TMS for MDD
Neuronetics
NCT07147218
Investigating the Neural Mechanisms of Repetitive Brain Stimulation With Invasive and Noninvasive Electrophysiology in Humans
Stanford University
NCT05996900
Mood Effects of Serotonin Agonists: Depression
University of Chicago
NCT07017478
Using Electrophysiology to Index Non-invasive Brain Stimulation Effects on Reward System Functioning in Depression
San Francisco Veterans Affairs Medical Center
NCT05194098
Accelerated Intermittent Theta Burst in Treatment-Naive Adolescents
University of Texas at Austin
NCT06523439
Using TMS to Understand Neural Processes of Social Motivation
Auburn University
NCT06274112
Feasibility of Home-Based Intermittent 60Hz Light Therapy for Major Depressive Disorder (MDD)
NYU Langone Health
NCT07111390
Mindful Self-Compassion for Anxiety Disorders and Depression
Georgetown University
NCT05671419
Decoding and Modulating Affective Brain States
University of Pennsylvania
NCT05437705
A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression
Sirtsei Pharmaceuticals
NCT06570369
The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
Yale University
NCT05786066
Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy
Michigan State University
NCT06529029
In-patient SCC TMS
University of California, Los Angeles
NCT05645575
Accelerated TMS for Perinatal Depression
Brigham and Women's Hospital
NCT06968390
Antiviral Treatment OF Cytomegalovirus IN Depression
Laureate Institute for Brain Research
NCT04724447
Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder
Massachusetts General Hospital
NCT03748446
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
Sharmin Ghaznavi
NCT06247839
Linking Affective Dynamics in Response to Daily Stress to Peripheral Vascular Function in Working Age Adults
University of Delaware
NCT06860724
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 24 |
| Phase 2 | 57 |
| Phase 3 | 45 |
| Phase 4 | 29 |
Top Sponsors
Named interventions
Most-linked intervention names on Major Depressive Disorder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Major Depressive Disorder trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Major Depressive Disorder page
283 registered trials, 109 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 109 Major Depressive Disorder trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Massachusetts General Hospital sponsors the most Major Depressive Disorder trials on record, review their full trial history before evaluating a specific study. See Massachusetts General Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Major Depressive Disorder condition card totals 283 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.